Our Pipeline
Product ID
Indication focus
Modality
Phase
INND-101
Autoimmune disorders driven by autoreactive B-cell and plasma-cell activity
CD20/BCMA-EVE16 via CD8A-targeted LNP
Preclinical
expected IIT start in September 2026
INND-101 is a targeted LNP therapy encapsulating two mRNA constructs encoding αCD20-EVE16 and αBCMA-EVE16 receptors. In both constructs, the EVE16 Fc-binding domain is engineered to silence ADCC and ADCP activity, minimizing the risk of unintended activation by autoreactive circulating antibodies. Following systemic intravenous administration, the LNP selectively delivers mRNA to CD8⁺ T cells, NK cells, and monocyte/macrophage populations. Transiently engineered immune cells then mediate controlled depletion of B cells, plasmablasts, and plasma cells - addressing the underlying drivers of antibody-mediated autoimmune disease.
INND-101
Indication Focus
Autoimmune disorders driven by autoreactive B-cell and plasma-cell activity
CD20/BCMA-EVE16 via CD8A-targeted LNP
Modality
Preclinical
Phase
expected IIT start in September 2026
INND-101 is a targeted LNP therapy encapsulating two mRNA constructs encoding αCD20-EVE16 and αBCMA-EVE16 receptors. In both constructs, the EVE16 Fc-binding domain is engineered to silence ADCC and ADCP activity, minimizing the risk of unintended activation by autoreactive circulating antibodies. Following systemic intravenous administration, the LNP selectively delivers mRNA to CD8⁺ T cells, NK cells, and monocyte/macrophage populations. Transiently engineered immune cells then mediate controlled depletion of B cells, plasmablasts, and plasma cells - addressing the underlying drivers of antibody-mediated autoimmune disease.
INND-201
Multiple myeloma
BCMA-EVE16 via CD7-targeted LNP
Preclinical
INND-201 is a targeted LNP encapsulating a linear mRNA construct encoding αBCMA-EVE16. The Fc-binding domain of EVE16 is engineered to enhance ADCC and ADCP activity, enabling synergistic interaction with monoclonal antibodies. Following intravenous administration, the therapy selectively delivers mRNA to CD7⁺ T cells, NK cells, and monocyte/macrophage populations. The transiently engineered immune cells are designed to potently deplete BCMA+ multiple myeloma cells. INND-201 is being evaluated as a combination therapy with approved anti-myeloma monoclonal antibodies to amplify therapeutic potency through complementary mechanisms.
INND-201
Indication Focus
Multiple myeloma
BCMA-EVE16 via CD7-targeted LNP
Modality
Preclinical
Phase
INND-201 is a targeted LNP encapsulating a linear mRNA construct encoding αBCMA-EVE16. The Fc-binding domain of EVE16 is engineered to enhance ADCC and ADCP activity, enabling synergistic interaction with monoclonal antibodies. Following intravenous administration, the therapy selectively delivers mRNA to CD7⁺ T cells, NK cells, and monocyte/macrophage populations. The transiently engineered immune cells are designed to potently deplete BCMA+ multiple myeloma cells. INND-201 is being evaluated as a combination therapy with approved anti-myeloma monoclonal antibodies to amplify therapeutic potency through complementary mechanisms.
INND-301
EGFR-expressing solid tumors
EGFR-EVE16 via CD7-targeted LNP
Preclinical
INND-301 is a targeted LNP encapsulating a linear mRNA construct encoding αEGFR-EVE16. The Fc-binding domain is engineered to enhance ADCC and ADCP activity, enabling synergistic activity with clinical monoclonal antibodies. Following systemic intravenous administration, the therapy selectively delivers mRNA to CD7⁺ T cells, NK cells, and monocyte/macrophage populations. The transiently engineered immune cells are designed to mediate potent cytotoxicity against EGFR-expressing solid tumors.
INND-301
Indication Focus
EGFR-expressing solid tumors
EGFR-EVE16 via CD7-targeted LNP
Modality
Preclinical
Phase
INND-301 is a targeted LNP encapsulating a linear mRNA construct encoding αEGFR-EVE16. The Fc-binding domain is engineered to enhance ADCC and ADCP activity, enabling synergistic activity with clinical monoclonal antibodies. Following systemic intravenous administration, the therapy selectively delivers mRNA to CD7⁺ T cells, NK cells, and monocyte/macrophage populations. The transiently engineered immune cells are designed to mediate potent cytotoxicity against EGFR-expressing solid tumors.